Inovio Pharmaceuticals Inc vs Park Hotels & Resorts Inc. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.96 (market cap $103.19M), while Park Hotels & Resorts Inc. Common Stock trades at $15.12 (market cap $3.14B). The key difference: Park Hotels & Resorts Inc. Common Stock is far larger — about 30.4× Inovio Pharmaceuticals Inc's market cap, and Park Hotels & Resorts Inc. Common Stock pays a 6.41% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Park Hotels & Resorts Inc. Common Stock for 0 Days on average.
| INO | PK | |
|---|---|---|
Market Cap | $103.19M | $3.14B |
Volume | 8,461,580 | 3,553,985 |
Sector | Health | Real Estate |
52-Week High | $2.60 | $16.17 |
52-Week Low | $0.66 | $9.84 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $6.98B |
Dividend Yield | — | 6.41% |
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Park Hotels & Resorts Inc. is a US lodging REIT, spun off from Hilton Worldwide in 2017, that owns a portfolio of premium-branded hotels and resorts in major urban, resort, and convention markets.
Read more on PK →